Literature DB >> 9242370

Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells.

Y Niihara1, C R Zerez, D S Akiyama, K R Tanaka.   

Abstract

Sickle red blood cells (RBCs) have been shown to have an increase in total nicotinamide adenine dinucleotide (NAD) content by an as-yet-unknown mechanism. Because glutamine is an essential precursor in NAD biosynthesis, we have examined the rates of active RBC glutamine transport and glutamine transport kinetics with Michaelis-Menten constant (K[m]) and maximum velocity (V[max]) in RBCs from patients with sickle cell disease, patients with high reticulocyte counts, and normal volunteers. In addition, plasma and RBC levels of glutamine and glutamate in the three groups were analyzed. The rate of active glutamate transport in sickle RBCs increased threefold over that in high-reticulocyte RBCs and increased 15-fold over that in normal RBCs. Glutamine transport K(m) in sickle RBCs was decreased fivefold in comparison with that in the high-reticulocyte group and that in normal control subjects. Glutamine transport V(max) for sickle RBCs was twofold and eightfold higher in comparison with those in the high-reticulocyte RBCs and normal control RBCs, respectively. Finally, the level of RBC glutamate (a byproduct of glutamine in NAD synthesis) in the sickle group was significantly increased in comparison with that in the high-reticulocyte group, whereas the RBC glutamine level was not. The higher glutamate level in sickle cells may suggest a higher glutamine turnover in these cells. These data suggest that sickle RBCs have an increased glutamine availability and affinity that may facilitate the increase in total NAD in sickle RBCs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242370     DOI: 10.1016/s0022-2143(97)90062-7

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  18 in total

1.  Pharmacological management of sickle cell disease.

Authors:  Uche Anadu Ndefo; Angie Eaton Maxwell; Huong Nguyen; Tochukwu L Chiobi
Journal:  P T       Date:  2008-04

Review 2.  Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.

Authors:  Varun Sagi; Donovan A Argueta; Stacy Kiven; Kalpna Gupta
Journal:  Complement Ther Med       Date:  2020-05-11       Impact factor: 2.446

Review 3.  L-glutamine for sickle cell disease: Knight or pawn?

Authors:  Alina Sadaf; Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-27

4.  Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.

Authors:  Jon A Detterich; Honglei Liu; Silvie Suriany; Roberta M Kato; Patjanaporn Chalacheva; Bruke Tedla; Payal M Shah; Michael C Khoo; John C Wood; Thomas D Coates; Ginger L Milne; Joo-Yeun Oh; Rakesh P Patel; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2019-07-03       Impact factor: 7.376

5.  Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data.

Authors:  Julia E Raftos; Stephney Whillier; Philip W Kuchel
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

Review 6.  βCysteine 93 in human hemoglobin: a gateway to oxidative stability in health and disease.

Authors:  Abdu I Alayash
Journal:  Lab Invest       Date:  2020-09-26       Impact factor: 5.662

7.  Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.

Authors:  Sirsendu Jana; Michael Brad Strader; Fantao Meng; Wayne Hicks; Tigist Kassa; Ivan Tarandovskiy; Silvia De Paoli; Jan Simak; Michael R Heaven; John D Belcher; Gregory M Vercellotti; Abdu I Alayash
Journal:  JCI Insight       Date:  2018-11-02

8.  Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

Authors:  Claudia R Morris; Jung H Suh; Ward Hagar; Sandra Larkin; D Anton Bland; Martin H Steinberg; Elliott P Vichinsky; Mark Shigenaga; Bruce Ames; Frans A Kuypers; Elizabeth S Klings
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

9.  Role of aminotransferases in glutamate metabolism of human erythrocytes.

Authors:  James J Ellinger; Ian A Lewis; John L Markley
Journal:  J Biomol NMR       Date:  2011-03-06       Impact factor: 2.835

Review 10.  Pain in sickle cell disease: current and potential translational therapies.

Authors:  Varun Sagi; Aditya Mittal; Huy Tran; Kalpna Gupta
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.